Director Quality Control Operations
Vaxcyte
Director Quality Control Operations
Vaxcyte
Develops broad-spectrum vaccines for bacterial infections
The Director of QC Operations leads the QC Operations team and is accountable for day-to-day Quality Control execution across Vaxcyte contract manufacturing and contract testing network. The role ensures the current business has the QC support it needs, that testing and release happen on time, and that Quality Control operates in a compliant, inspection-ready state through VAX-31 BLA and into commercial supply.
As the executive function of Quality Control, the role provides leadership and oversight for implementation of the approved analytical control strategy and specifications at the contract manufacturing and contract testing organizations. Working closely with Analytical Development, Analytical Science and Technology, Stability, Quality Assurance, Regulatory Affairs, and the Analytical Technical Leads, this role is critical to timely, compliant, and uninterrupted release of Vaxcyte products.
Equal Opportunity
We are an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability or veteran status.
Recruitment Fraud Notice
Please be aware of fraud or scams from individuals, organizations and/or internet sites claiming to represent Vaxcyte in recruitment activities. Vaxcyte has an established recruitment process for all positions prior to issuing an offer for employment and we will never extend unsolicited employment offers or ask candidates to provide financial or sensitive personal information as part of the application process. All legitimate communication from Vaxcyte will come from an official @vaxcyte.com email address. Qualified and interested candidates should apply to current openings at vaxcyte.com/careers.
Vaxcyte develops vaccines to prevent bacterial infections, focusing on broad-spectrum pneumococcal vaccines and other targets like Group A Strep, periodontitis, and Shigella. Its lead product, VAX-24, covers 24 Streptococcus pneumoniae strains and is produced using the XpressCF cell-free protein synthesis platform, which enables multi-strain conjugate vaccines. The company differentiates itself by combining cell-free manufacturing with broad strain coverage and has FDA Breakthrough Therapy designation for VAX-24, helping speed development. Its goal is to bring broadly protective bacterial vaccines to market, reduce serious infections worldwide, and expand its portfolio with products like VAX-31 and additional preclinical candidates.
Explore more opportunities at Vaxcyte